News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
382,057 Results
Type
Article (18607)
Company Profile (290)
Press Release (363160)
Section
Business (111560)
Career Advice (431)
Deals (21563)
Drug Delivery (53)
Drug Development (61711)
Employer Resources (52)
FDA (9322)
Job Trends (7628)
News (202269)
Policy (16932)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1256)
Accelerated approval (2)
Adcomms (15)
Allergies (63)
Alliances (28496)
ALS (69)
Alzheimer's disease (1073)
Antibody-drug conjugate (ADC) (88)
Approvals (9336)
Artificial intelligence (155)
Autoimmune disease (13)
Automation (7)
Bankruptcy (198)
Best Places to Work (6780)
BIOSECURE Act (6)
Biosimilars (48)
Biotechnology (238)
Bladder cancer (53)
Brain cancer (21)
Breast cancer (182)
Cancer (1576)
Cardiovascular disease (128)
Career advice (375)
Career pathing (5)
CAR-T (126)
Cell therapy (351)
Cervical cancer (14)
Clinical research (50403)
Collaboration (598)
Compensation (248)
Complete response letters (18)
COVID-19 (1412)
CRISPR (37)
C-suite (159)
Cystic fibrosis (89)
Data (1649)
Denatured (12)
Depression (34)
Diabetes (178)
Diagnostics (3067)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (90)
Drug pricing (61)
Drug shortages (17)
Duchenne muscular dystrophy (84)
Earnings (47474)
Editorial (26)
Employer branding (5)
Employer resources (46)
Events (61802)
Executive appointments (454)
FDA (10172)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (548)
Gene editing (91)
Generative AI (14)
Gene therapy (251)
GLP-1 (441)
Government (1945)
Grass and pollen (3)
Guidances (35)
Healthcare (9830)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (89)
Indications (22)
Infectious disease (1499)
Inflammatory bowel disease (119)
Inflation Reduction Act (10)
Influenza (27)
Intellectual property (68)
Interviews (60)
IPO (11471)
IRA (25)
Job creations (1232)
Job search strategy (335)
Kidney cancer (7)
Labor market (9)
Layoffs (224)
Leadership (5)
Legal (2935)
Liver cancer (46)
Lung cancer (219)
Lymphoma (98)
Machine learning (1)
Management (12)
Manufacturing (163)
MASH (52)
Medical device (6236)
Medtech (6238)
Mergers & acquisitions (10523)
Metabolic disorders (484)
Multiple sclerosis (61)
NASH (14)
Neurodegenerative disease (62)
Neuropsychiatric disorders (24)
Neuroscience (1475)
NextGen: Class of 2025 (2951)
Non-profit (1383)
Northern California (1889)
Now hiring (21)
Obesity (256)
Opinion (141)
Ovarian cancer (68)
Pain (59)
Pancreatic cancer (63)
Parkinson's disease (112)
Partnered (9)
Patents (152)
Patient recruitment (79)
Peanut (40)
People (31872)
Pharmaceutical (51)
Pharmacy benefit managers (11)
Phase I (16828)
Phase II (22893)
Phase III (15774)
Pipeline (864)
Podcasts (48)
Policy (61)
Postmarket research (1272)
Preclinical (6853)
Press Release (36)
Prostate cancer (74)
Psychedelics (35)
Radiopharmaceuticals (228)
Rare diseases (312)
Real estate (2114)
Recruiting (19)
Regulatory (13402)
Reports (19)
Research institute (1210)
Resumes & cover letters (56)
Rett syndrome (3)
RNA editing (3)
RSV (22)
Schizophrenia (58)
Series A (107)
Series B (65)
Service/supplier (2)
Sickle cell disease (45)
Southern California (1657)
Special edition (11)
Spinal muscular atrophy (124)
Sponsored (22)
Startups (2244)
State (1)
Stomach cancer (8)
Supply chain (33)
The Weekly (34)
United States (15640)
Vaccines (307)
Venture capitalists (31)
Webinars (8)
Weight loss (152)
Women's health (17)
Worklife (5)
Date
Today (102)
Last 7 days (500)
Last 30 days (1975)
Last 365 days (25996)
2025 (5970)
2024 (27027)
2023 (29939)
2022 (36105)
2021 (38010)
2020 (33991)
2019 (23986)
2018 (17734)
2017 (19623)
2016 (17016)
2015 (20742)
2014 (15130)
2013 (11186)
2012 (11462)
2011 (12016)
2010 (11388)
Location
Africa (286)
Alabama (41)
Alaska (3)
Arizona (94)
Arkansas (8)
Asia (26380)
Australia (5660)
California (4297)
Canada (1515)
China (384)
Colorado (173)
Connecticut (201)
Delaware (100)
Europe (51140)
Florida (584)
Georgia (144)
Idaho (21)
Illinois (275)
India (18)
Indiana (155)
Iowa (1)
Japan (115)
Kansas (65)
Kentucky (8)
Louisiana (7)
Maine (43)
Maryland (561)
Massachusetts (3349)
Michigan (93)
Minnesota (197)
Mississippi (1)
Missouri (44)
Montana (18)
Nebraska (9)
Nevada (41)
New Hampshire (49)
New Jersey (1248)
New Mexico (14)
New York (1186)
North Carolina (696)
North Dakota (5)
Northern California (1889)
Ohio (124)
Oklahoma (9)
Oregon (23)
Pennsylvania (904)
Puerto Rico (5)
Rhode Island (16)
South America (448)
South Carolina (10)
Southern California (1657)
Tennessee (52)
Texas (582)
Utah (91)
Virginia (93)
Washington D.C. (36)
Washington State (431)
West Virginia (2)
Wisconsin (20)
382,057 Results for "psioxus therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Business
PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
PsiOxus Therapeutics, Ltd. today announces the appointment of Howard Davis, Ph.D., as Chief Executive Officer.
August 11, 2022
·
5 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Genetown
Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors.
January 5, 2023
·
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Press Releases
Nemysis Limited Announces Collaboration With Avia Pharma AB as IHAT Distributor in Nordic Region
March 14, 2025
·
2 min read
Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
February 25, 2025
·
6 min read
Obesity
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to
BioSpace
that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.
March 7, 2025
·
2 min read
·
Dan Samorodnitsky
Business
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Tryp Therapeutics, Inc. today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have been granted a pivotal 2 cent waiver by the Australian Securities Exchange (“ASX”).
January 26, 2024
·
5 min read
Press Releases
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
March 12, 2025
·
5 min read
1 of 38,206
Next
